NRP2 and systemic sclerosis: Such a scenario is further supported by the evidence that treatment of LMVECs with SSc serum also resulted in a significant downregulation of NRP-2, a key co-receptor that modulates VEGF-C/VEGFR-3 signaling in lymphatic vessel development and post-natal lymphangiogenesis [14,30,41].